To offer the services, Atherotech is utilizing BG Medicine’s Galectin-3 test as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.
The Galectin-3 test has obtained the US Food and Drug Administration approval in November 2010.
BG Medicine is also focusing on developing CardioSCORE blood test designed to identify individuals who are at high risk for near-term major cardiovascular events such as heart attack and stroke.
